Cases & Deals

Chiesi acquires three hospital products from The Medicines Company

Clients Chiesi Farmaceutici S.p.A.

Jones Day advised Chiesi Farmaceutici S.p.A., a pharmaceutical company focused on commercializing products for the hospital and adjacent specialty markets, in its acquisition of three cardiovascular products -- Kengreal® (cangrelor), Cleviprex® (clevidipine), and rights to Argatroban® for Injection –- from The Medicines Company. The Medicines Company received approximately $262 million in cash at closing, and is entitled to receive up to $480 million in sales-based milestone and royalty payment obligations.